ResMed Stock Collapses After Eli Lilly's Weight-Loss Drug Reduces Sleep Apnea Events Investor's Business DailyWhy a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling InvestopediaLilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution | Eli Lilly and Company Investors | Eli Lilly and CompanyWeight-Loss Drug Zepbound Offers a New Way to Treat Sleep Apnea The New York TimesEli Lilly seeks to expand Zepbound use to treat sleep apnea Yahoo Finance